CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
256-270 of 1187
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
CME/CEShifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Stephen J. Greene, MD
Anne Louise Peters, MD
The Future of HNSCC: Aligning Teams, Transforming Care
CME/CEThe Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Juan Badimon, PhD, FAHA
- advertisement
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS
Anjali Owens, MD
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
Anjali Owens, MD
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
MinuteCE®From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS
Anjali Owens, MD
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS
Anjali Owens, MD
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Maria Pabon, MD
Robert J. Mentz, MD, FHFSA, FACC
- advertisement
Safety in oHCM Therapy: How and When to Transition Treatment?
MinuteCE®Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
MinuteCE®Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc
Anjali Owens, MD
